Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571961 · ClinicalTrials.gov registry record · NA
Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00571961 is a NA study that has completed, run by Yale University. The registered enrollment target is 12 participants.
The verdict
NCT00571961, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The main purpose of this protocol is to study the effect of an HIV medication, Kaletra (lopinavir/ritonavir), on buprenorphine in non-HIV infected people who have been receiving the same dose of buprenorphine for at least 3 weeks. Study Hypothesis: Kaletra (lopinavir/ritonavir) will increase buprenorphine plasma levels without any significant clinical effect on the subject or need for dose adjustment.
Interventions
- DRUG buprenorphine
- DRUG Kaletra (lopinavir/ritonavir)
- OTHER Clinical evaluations/Blood draws
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571961
The ClinicalTrials.gov registry entry for NCT00571961 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which buprenorphine is the first listed.
NCT00571961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571961 about?
NCT00571961 is a clinical study titled "Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)". The main purpose of this protocol is to study the effect of an HIV medication, Kaletra (lopinavir/ritonavir), on buprenorphine in non-HIV infected people who have been receiving the same dose of buprenorphine for at least 3 weeks. Study Hypothesis: Kaletra (lopinavir/ritonavir) will increase bupre...
What is the current status of trial NCT00571961?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2007-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00571961?
The interventions under investigation include: buprenorphine (DRUG), Kaletra (lopinavir/ritonavir) (DRUG), Clinical evaluations/Blood draws (OTHER).
Who is sponsoring clinical trial NCT00571961?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.